This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Share this article

Follow by Email
Facebook
Twitter

Comment: Long-term albumin in cirrhosis: is it the ANSWER?

Garcia-Tsao G
4 December, 2019  

ANSWER was an open-label, randomised, pragmatic trial conducted in Italy.

It compared the use of human albumin versus symptomatic standard of care (anti-aldosterone agents and large-volume paracentesis) to reduce the mortality and morbidity in patients with decompensated cirrhosis and persistent ascites.

The author comments on and summarises the main findings of this proof-of-concept study and discusses its limitations and the potential impact on clinical practice in light of data obtained from other studies of albumin in similar indications.

The mechanisms of action and dosing schedule of albumin are described, as well as its disadvantages such as high cost.